Randomized, blind, controlled trial of transdermal rotigotine in early Parkinson disease.
Identifieur interne : 000168 ( PubMed/Corpus ); précédent : 000167; suivant : 000169Randomized, blind, controlled trial of transdermal rotigotine in early Parkinson disease.
Auteurs : R Watts ; J. Jankovic ; C. Waters ; A. Rajput ; B. Boroojerdi ; J. RaoSource :
- Neurology ; 2007.
English descriptors
- KwdEn :
- Administration, Cutaneous, Aged, Dopamine Agonists (administration & dosage), Double-Blind Method, Female, Humans, Male, Middle Aged, Parkinson Disease (drug therapy), Parkinson Disease (epidemiology), Parkinson Disease (physiopathology), Tetrahydronaphthalenes (administration & dosage), Thiophenes (administration & dosage), Time Factors.
- MESH :
- chemical , administration & dosage : Dopamine Agonists, Tetrahydronaphthalenes, Thiophenes.
- drug therapy : Parkinson Disease.
- epidemiology : Parkinson Disease.
- physiopathology : Parkinson Disease.
- Administration, Cutaneous, Aged, Double-Blind Method, Female, Humans, Male, Middle Aged, Time Factors.
Abstract
This multicenter, randomized, double-blind study was performed to compare the safety and efficacy of the once-daily dopamine agonist rotigotine, in a continuous-dosing transdermal-patch formulation, vs placebo in patients with early-stage Parkinson disease (PD).
DOI: 10.1212/01.wnl.0000252355.79284.22
PubMed: 17202432
Links to Exploration step
pubmed:17202432Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Randomized, blind, controlled trial of transdermal rotigotine in early Parkinson disease.</title><author><name sortKey="Watts, R L" sort="Watts, R L" uniqKey="Watts R" first="R" last="Watts">R Watts</name><affiliation><nlm:affiliation>Department of Neurology, University of Alabama at Birmingham, Birmingham, AL 35233-0017, USA. rlwatts@uab.edu</nlm:affiliation></affiliation></author><author><name sortKey="Jankovic, J" sort="Jankovic, J" uniqKey="Jankovic J" first="J" last="Jankovic">J. Jankovic</name></author><author><name sortKey="Waters, C" sort="Waters, C" uniqKey="Waters C" first="C" last="Waters">C. Waters</name></author><author><name sortKey="Rajput, A" sort="Rajput, A" uniqKey="Rajput A" first="A" last="Rajput">A. Rajput</name></author><author><name sortKey="Boroojerdi, B" sort="Boroojerdi, B" uniqKey="Boroojerdi B" first="B" last="Boroojerdi">B. Boroojerdi</name></author><author><name sortKey="Rao, J" sort="Rao, J" uniqKey="Rao J" first="J" last="Rao">J. Rao</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2007">2007</date><idno type="doi">10.1212/01.wnl.0000252355.79284.22</idno><idno type="RBID">pubmed:17202432</idno><idno type="pmid">17202432</idno><idno type="wicri:Area/PubMed/Corpus">000168</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Randomized, blind, controlled trial of transdermal rotigotine in early Parkinson disease.</title><author><name sortKey="Watts, R L" sort="Watts, R L" uniqKey="Watts R" first="R" last="Watts">R Watts</name><affiliation><nlm:affiliation>Department of Neurology, University of Alabama at Birmingham, Birmingham, AL 35233-0017, USA. rlwatts@uab.edu</nlm:affiliation></affiliation></author><author><name sortKey="Jankovic, J" sort="Jankovic, J" uniqKey="Jankovic J" first="J" last="Jankovic">J. Jankovic</name></author><author><name sortKey="Waters, C" sort="Waters, C" uniqKey="Waters C" first="C" last="Waters">C. Waters</name></author><author><name sortKey="Rajput, A" sort="Rajput, A" uniqKey="Rajput A" first="A" last="Rajput">A. Rajput</name></author><author><name sortKey="Boroojerdi, B" sort="Boroojerdi, B" uniqKey="Boroojerdi B" first="B" last="Boroojerdi">B. Boroojerdi</name></author><author><name sortKey="Rao, J" sort="Rao, J" uniqKey="Rao J" first="J" last="Rao">J. Rao</name></author></analytic><series><title level="j">Neurology</title><idno type="e-ISSN">1526-632X</idno><imprint><date when="2007" type="published">2007</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Administration, Cutaneous</term><term>Aged</term><term>Dopamine Agonists (administration & dosage)</term><term>Double-Blind Method</term><term>Female</term><term>Humans</term><term>Male</term><term>Middle Aged</term><term>Parkinson Disease (drug therapy)</term><term>Parkinson Disease (epidemiology)</term><term>Parkinson Disease (physiopathology)</term><term>Tetrahydronaphthalenes (administration & dosage)</term><term>Thiophenes (administration & dosage)</term><term>Time Factors</term></keywords><keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Dopamine Agonists</term><term>Tetrahydronaphthalenes</term><term>Thiophenes</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Parkinson Disease</term></keywords><keywords scheme="MESH" qualifier="epidemiology" xml:lang="en"><term>Parkinson Disease</term></keywords><keywords scheme="MESH" qualifier="physiopathology" xml:lang="en"><term>Parkinson Disease</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Administration, Cutaneous</term><term>Aged</term><term>Double-Blind Method</term><term>Female</term><term>Humans</term><term>Male</term><term>Middle Aged</term><term>Time Factors</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">This multicenter, randomized, double-blind study was performed to compare the safety and efficacy of the once-daily dopamine agonist rotigotine, in a continuous-dosing transdermal-patch formulation, vs placebo in patients with early-stage Parkinson disease (PD).</div></front></TEI><pubmed><MedlineCitation Owner="NLM" Status="MEDLINE"><PMID Version="1">17202432</PMID><DateCreated><Year>2007</Year><Month>01</Month><Day>23</Day></DateCreated><DateCompleted><Year>2007</Year><Month>02</Month><Day>21</Day></DateCompleted><DateRevised><Year>2008</Year><Month>01</Month><Day>02</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1526-632X</ISSN><JournalIssue CitedMedium="Internet"><Volume>68</Volume><Issue>4</Issue><PubDate><Year>2007</Year><Month>Jan</Month><Day>23</Day></PubDate></JournalIssue><Title>Neurology</Title><ISOAbbreviation>Neurology</ISOAbbreviation></Journal><ArticleTitle>Randomized, blind, controlled trial of transdermal rotigotine in early Parkinson disease.</ArticleTitle><Pagination><MedlinePgn>272-6</MedlinePgn></Pagination><Abstract><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">This multicenter, randomized, double-blind study was performed to compare the safety and efficacy of the once-daily dopamine agonist rotigotine, in a continuous-dosing transdermal-patch formulation, vs placebo in patients with early-stage Parkinson disease (PD).</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">Patients were randomized to receive placebo (n = 96) or rotigotine (n = 181), starting at 2 mg/24 h (10-cm(2) patch size; 4.5-mg total drug content), titrated weekly up to 6 mg/24 h (30-cm(2) patch size; 13.5-mg total drug content), and then maintained for 6 months. The primary efficacy measures were 1) the change in the Unified Parkinson's Disease Rating Scale (UPDRS) scores (parts II and III) from baseline to end of treatment and 2) responder rates (patients with > or =20% improvement).</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Patients receiving rotigotine had a mean absolute difference of 5.28 (+/-1.18) points lower in UPDRS subtotal scores compared with those receiving placebo (p < 0.0001). The mean change in part III motor scores was -3.50 (+/-7.26) (n = 177) and was the greatest contributor to UPDRS improvement. The rotigotine group had more responders (48 vs 19%; p < 0.0001). The most commonly reported adverse events were application site reactions (44% rotigotine vs 12% placebo), nausea (41 vs17%), somnolence (33 vs 20%), and dizziness (19 vs 13%), and most were mild or moderate in intensity.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Transdermal rotigotine, when titrated to a dosage of 6 mg/24 h, was effective for the treatment of early-stage Parkinson disease in this trial. Adverse events were similar to those found with other transdermal systems and dopamine agonists.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Watts</LastName><ForeName>R L</ForeName><Initials>RL</Initials><AffiliationInfo><Affiliation>Department of Neurology, University of Alabama at Birmingham, Birmingham, AL 35233-0017, USA. rlwatts@uab.edu</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jankovic</LastName><ForeName>J</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Waters</LastName><ForeName>C</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Rajput</LastName><ForeName>A</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Boroojerdi</LastName><ForeName>B</ForeName><Initials>B</Initials></Author><Author ValidYN="Y"><LastName>Rao</LastName><ForeName>J</ForeName><Initials>J</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D017428">Clinical Trial, Phase III</PublicationType><PublicationType UI="D003160">Comparative Study</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016448">Multicenter Study</PublicationType><PublicationType UI="D016449">Randomized Controlled Trial</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2007</Year><Month>01</Month><Day>03</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Neurology</MedlineTA><NlmUniqueID>0401060</NlmUniqueID><ISSNLinking>0028-3878</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018491">Dopamine Agonists</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D013764">Tetrahydronaphthalenes</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D013876">Thiophenes</NameOfSubstance></Chemical><Chemical><RegistryNumber>92206-54-7</RegistryNumber><NameOfSubstance UI="C047508">N 0437</NameOfSubstance></Chemical></ChemicalList><CitationSubset>AIM</CitationSubset><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Arch Neurol. 2007 Dec;64(12):1800-1; author reply 1801</RefSource><PMID Version="1">18071051</PMID></CommentsCorrections><CommentsCorrections RefType="ErratumIn"><RefSource>Neurology. 2007 Dec 4;69(23):2187</RefSource></CommentsCorrections><CommentsCorrections RefType="ErratumIn"><RefSource>Neurology. 2007 Aug 7;69(6):617</RefSource></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName MajorTopicYN="N" UI="D000279">Administration, Cutaneous</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D000368">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D018491">Dopamine Agonists</DescriptorName><QualifierName MajorTopicYN="Y" UI="Q000008">administration & dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D004311">Double-Blind Method</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D005260">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D008297">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D008875">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D010300">Parkinson Disease</DescriptorName><QualifierName MajorTopicYN="Y" UI="Q000188">drug therapy</QualifierName><QualifierName MajorTopicYN="N" UI="Q000453">epidemiology</QualifierName><QualifierName MajorTopicYN="N" UI="Q000503">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D013764">Tetrahydronaphthalenes</DescriptorName><QualifierName MajorTopicYN="Y" UI="Q000008">administration & dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D013876">Thiophenes</DescriptorName><QualifierName MajorTopicYN="Y" UI="Q000008">administration & dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D013997">Time Factors</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="aheadofprint"><Year>2007</Year><Month>1</Month><Day>3</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2007</Year><Month>1</Month><Day>5</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2007</Year><Month>2</Month><Day>22</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2007</Year><Month>1</Month><Day>5</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pii">01.wnl.0000252355.79284.22</ArticleId><ArticleId IdType="doi">10.1212/01.wnl.0000252355.79284.22</ArticleId><ArticleId IdType="pubmed">17202432</ArticleId></ArticleIdList></PubmedData></pubmed></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/JankovicV1/Data/PubMed/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000168 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd -nk 000168 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Santé
|area= JankovicV1
|flux= PubMed
|étape= Corpus
|type= RBID
|clé= pubmed:17202432
|texte= Randomized, blind, controlled trial of transdermal rotigotine in early Parkinson disease.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/RBID.i -Sk "pubmed:17202432" \
| HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd \
| NlmPubMed2Wicri -a JankovicV1
| This area was generated with Dilib version V0.6.19. |  |